[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"low-anterior-resection-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:low-anterior-resection-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,45,86,112,134,159,186,207,234,256,293,319,339,364,386],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609835","transanal-irrigation-for-the-management-of-early-low-anterior-resection-syndrome-lars-100609835",false,"NCT07219745","Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)","Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS): A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adults (≥18 years-old) patients who underwent a LAR for any indication via open, laparoscopic, robotic, or transanal total mesorectal excision, with creation of a diverting loop ileostomy,\n2. have confirmed anastomotic healing demonstrated by flexible sigmoidoscopy and CT scan with rectally-administered water soluble contrast or gastrograffin enema,\n3. are planned for an ileostomy closure operation, and\n4. are in the first 12 months post-LAR operation\n\nExclusion Criteria:\n\n1. Inability to comprehend English or Spanish or provide informed consent (Note: after the English documents are approved, the study team plans to obtain a Spanish consent and study documents),\n2. ongoing chemotherapy or radiotherapy, and\n3. ongoing anastomotic complication.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Transanal irrigation (TAI) has shown to improve fecal incontinence and increase quality of life in patients with low anterior resection syndrome (LARS). This trial is a small study being conducted to determine whether a larger trial is feasible. Investigators are also doing this research to see if TAI impacts quality of life and improves bowel function within the early post-operative period (1-12 months).\n\nThis treatment is designed for participants to have more control over their bowel movements and reduce the dependency on immediate access to the toilet.",[26,27],"Colorectal Cancer","Low Anterior Resection Syndrome",[29,30,27,31],"Transanal irrigation","Peristeen Transanal Irrigation System","LARS","NOT_YET_RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":20},"2026-10",{"date":40,"type":20},"2027-11",{"name":42,"class":43},"Case Comprehensive Cancer Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":57,"conditions":58,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":44},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":53,"type":20},400,[55,56],"PHASE2","PHASE3","This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[59,60,61,62,63,64,65,66,67,27,68],"Rectal Cancer","Total Neoadjuvant Treatment","Neoadjuvant Therapy","Radiotherapy","Chemotherapy","Organ Preservation","Radiotherapy Side Effect","Chemotherapy Side Effects","Chemoradiotherapy","Quality of Life",[70,60,71,62,63,67,64,65,72,73,74,75,27],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications","RECRUITING","2026-05-06",{"date":79,"type":36},"2026-05-11",{"date":81,"type":36},"2025-01-06",{"date":83,"type":20},"2029-12-27",{"name":85,"class":43},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100637029","understanding-and-tailored-treatment-of-low-anterior-resection-syndrome-100637029","NCT07573371","Understanding and Tailored Treatment of Low Anterior Resection Syndrome","PATO-LARS","Inclusion Criteria:\n\nGeneral:\n\n* Must be able to read and understand Danish.\n* All participants must be adults and \\>18 years and have full legal capacity.\n* Assessed by study personnel to have understood the research protocol, being able to comply with investigation procedures as well as ability to come to the hospital at the agreed timepoints, and to complete the trial.\n\nSpecific inclusion criteria for LARS patients:\n\n* Patients operated for rectal cancer with a rectal resection and sphincter preserving surgery at a minimum of three months postop.\n* If patients have received a temporary protective ileostomy, this should have been reversed for a minimum of three months postop.\n\nSpecific inclusion criteria for fecal incontinence patients and urge fecal incontinence patients\n\n* Patients planned for neuromodulation.\n* Satisfactory interoperative test results leading to permanent implantation of a pacemaker for sacral nerve modulation.\n\nSpecific inclusion criteria for \"watch and wait\" patients:\n\n• Rectum\u002Fcolon cancer patients treated with organ-preserving treatment, i.e., chemotherapy and radiotherapy with a complete clinical and radiological response at a minimum of 12 months posttreatment.\n\nExclusion Criteria:\n\nGeneral exclusion criteria\n\n* Persons that are not able to understand information\n* Connective tissue disorders\n* Parkinson's disease\n* Non-MRI compatible pacemaker, clips or other metal objects in the body. Patients implanted with a pacemaker for sacral nerve modulation will not undergo MRI postoperatively.\n* Piercings that cannot be removed before MRI\n* Claustrophobia\n* Allergic to latex\n* Abdominal diameter equal or more than 140 cm\n* Have other individual factors, in the opinion of the physician\u002Fhealthcare professional, in which participating is contraindicated\n* Participation in concomitant clinical trial\n* Known intestinal obstruction, significant intestinal strictures or perforation. If in doubt about intestinal stricture, the patient will be examined with MRI of the small intestine, colonoscopy or other supplementing examination\n* Disorders of swallowing\n* Pregnant women\n\nSpecific exclusion criterias for LARS patients\n\n* History of anastomotic leakage following rectal resection and sphincter preserving therapy\n* Evidens of local recurrence or dessimination of the cancer",{"count":94,"type":20},145,"OBSERVATIONAL","The goal of this observational study is to learn why some patients develop low anterior resection syndrome (LARS) after colorectal cancer treatment. The study also aims to identify different subtypes of LARS and understand which patients may respond to specific treatments.\n\nThe main questions it aims to answer are:\n\n* What physiological and imaging changes are associated with LARS?\n* How do patients with LARS differ from patients without LARS after colorectal cancer surgery?\n* Are there measurable differences between LARS, patients treated with organ-preserving chemoradiotherapy, and patients with fecal incontinence?\n\nParticipants will:\n\n* Complete advanced physiological and imaging assessments related to bowel function\n* Be compared with four control groups:\n\n  * patients without LARS after colorectal cancer surgery\n  * patients treated with organ-preserving chemoradiotherapy\n  * patients with fecal incontinence and urge fecal incontinence\n* Take part in a single study visit where all measurements are performed",[27,98,99,100],"Faecal Incontinence With Faecal Urgency","Faecal Incontinence","Colorectal (Colon or Rectal) Cancer Survivors",[31],"2026-05-01",{"date":104,"type":36},"2026-05-07",{"date":106,"type":36},"2024-09-17",{"date":108,"type":20},"2026-12-31",{"name":110,"class":43},"Aalborg University Hospital",3,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":44},"100548709","a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients-100548709","NCT06424522","A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients","Low Anterior Resection Syndrome: Retrograde Enema Program vs Medical Management","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Moderate to Severe LARS diagnosis\n* Patients with history of rectal cancer that was treated with proctectomy\n* Has undergone standard medical management without improvement of symptoms for 3-6 months\n\nExclusion Criteria:\n\n* Patients presenting with significant stricture that need a definitive surgical management strategy; patients with minor or clinically negligible strictures can still be candidates. Patients who are able to pass the catheter and the balloon per rectum may be candidates after a digital rectal exam at their initial visit\n* Patients with any chemo or radiation therapy in the last 6 months\n* Patients who currently have colorectal cancer\n* Patients with recurrent colorectal cancer\n* Patients who have undergone a colorectal surgical procedure within the last three months\n* Patients with progressive neurological disease\n* Patients with active or recurrent sacral infection\n* Patients \\\u003C 18 years old\n* Active sacral nerve simulator\n* Pregnant or planning to become pregnant during the treatment portion of the study\n* Altered mental status or mental disability that would alter ability to self-administer enema\n* Any reason the research team believes the subject is not an appropriate candidate for this study (i.e., transportation issues, history of no-show appointments, lack of reliable communications, vulnerable population(s), etc.)",{"count":120,"type":20},80,[23],"This clinical trial studies if a bowel management program with a retrograde rectal enema (RRE) for the treatment of low anterior resection syndrome (LARS) in rectal cancer patients is better than medical management alone. Rectal cancer treatment can include a procedure where part of the rectum with cancer is removed and the remaining part of the rectum is reconnected to the colon, this is called a low anterior resection of the rectum. LARS is a common condition that can develop after undergoing a low anterior resection of the rectum. LARS consists of any change in how the body performs defecation, the discharge of feces from the body, after undergoing a resection procedure. Patients with LARS may experience fecal urgency, incontinence, increased frequency, constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Patients may experience individual symptoms of LARS or a combination of them. A bowel management program assists patient's with identifying a specific bowel management regimen that works best for managing symptoms of LARS. A RRE consists of inserting a catheter through the anus into the rectum. The RRE is designed to assist fecal emptying. Medical management of LARS can include the use of fiber, loperamide hydrochloride, or pelvic floor physical therapy. Fiber may help relieve constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Loperamide hydrocholoride may help lessen fecal urgency, incontinence, or increased frequency. Pelvic floor physical therapy may help restore strength in the rectum possibly helping to improve symptoms of LARS. Participating in a bowel management program with a RRE may be more effective in treating LARS than medical management alone.",[27,124],"Rectal Carcinoma","2026-04-16",{"date":127,"type":36},"2026-04-21",{"date":129,"type":20},"2026-08-15",{"date":131,"type":20},"2028-12-31",{"name":133,"class":43},"Ohio State University Comprehensive Cancer Center",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":44},"100634308","phase-2-antegrade-intestinal-fluid-reinfusion-for-prevention-of-low-anterior-resection-syndrome-after-low-anterior-resection-a-single-center-prospective-randomized-controlled-trial-100634308","NCT07537998","Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.","Antegrade Intestinal Fluid Reinfusion Verse Water Infusion Through Prophylactic Ileal Stoma for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Patients with mid to low rectal cancer (within 10cm of the anal verge) who undergo radical DIXON+ileostomy surgery.\n* General situation is well and one can take care of themselves.\n* Anal digital examination confirms that the anastomotic site has fully healed 1 month after surgery.\n* The anal sphincter function is good, and the ilestomy reverse surgery has not been completed.\n* Regardless of whether preoperative radiotherapy or chemotherapy has been received.\n\nExclusion Criteria:\n\n* Patients with anastomotic leakage after rectal cancer surgery.\n* The patient's general physical condition is poor and they are unable to take care of themselves.\n* Expected inability to retract the stoma.\n* Patients with preoperative inflammatory bowel disease, such as ulcerative colitis, Crohn's disease, etc.\n* inability to treat according to the plan, poor compliance.","75 Years",{"count":143,"type":20},160,[55,56],"The goal of this clinical trial is to learn if antegrade intestinal fluid reinfusion works to prevent low anterior resection syndrome (LARS) in patients with prophylactic ileal stoma. The main questions it aims to answer are:\n\n1. Does it work to prevent LARS by antegrade intestinal fluid reinfusion before performing the ileostomy reversal surgery?\n2. Is antegrade intestinal fluid reinfusion more effective than water infusion in preventing LARS.\n\nParticipants will:\n\n1. Receive either antegrade intestinal fluid reinfusion or antegrade water infusion through ileal stoma based on the standard of care at 1 month after anterior rectal resection, until the ileostomy reversal.\n2. Keep a diary of their symptoms.",[27,59],[148,149],"low anterior resection syndrome","antegrade intestinal fluid reinfusion","2026-04-12",{"date":152,"type":36},"2026-04-17",{"date":154,"type":20},"2026-04-10",{"date":156,"type":20},"2028-04-10",{"name":158,"class":43},"Pei-Rong Ding",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":141,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":44},"100511746","comparison-of-postoperative-anal-function-between-parks-and-bacon-techniques-in-low-rectal-cancer-100511746","NCT05943444","Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer","Comparison of Postoperative Anal Function Between Different Anastomosis Techniques(Parks Versus Bacon) in Low Rectal Cancer: A Prospective, Multicentric and Randomized Controlled Study","Inclusion Criteria:\n\n1. Men or women, aged between 18 and 75 years;\n2. Pathological diagnosis of rectal cancer before operation, with the distance from the lower edge of the tumor to the dentate line ≤ 3cm by MR imaging;\n3. No local complications (including complete\u002F incomplete obstruction, active bleeding, local invasion of sphincter or levator ani, etc.) before operation;\n4. Suitable for anal preservation surgery discussed by MDT;\n5. Adequate bone marrow, liver, renal and cardiac function meeting the requirements of surgery and anesthesia;\n6. R0 resection is expected technically;\n7. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Previous history of malignant colorectal tumors;\n2. Complications such as obstruction and gastrointestinal bleeding that need an emergency operation;\n3. Unachievable R0 resection due to invasion of adjacent organs by primary tumor;\n4. Multiple primary tumors;\n5. History of other malignancy;\n6. Participation in other clinical trials within the previous 4 weeks of enrollment;\n7. ASA physical status score ≥ IV level and\u002For ECOG performance status ≥ 2;\n8. Intolerance of surgery due to liver, renal, cardiopulmonary or coagulation dysfunction, or underlying diseases;\n9. History of serious mental disorders;\n10. Women in pregnancy or lactation period;\n11. Uncontrolled infection before operation;\n12. Unsuitable to be included due to other clinical and laboratory conditions by the judgement of investigators.",{"count":167,"type":20},256,[23],"The goal of this study is to compare the postoperative anal function of patients with ultra-low rectal cancer after Parks operation (colon anal anastomosis) and Bacon operation (colon anal pull-out anastomosis), which may provide clinical evidence for the improvement of anal function and quality of life.\n\nThe main questions it aims to answer are: the difference of anal function 1 year after surgery type of study: clinical trial participant population: patients with low rectal cancer Participants will receive Parks operation of Bacon operation If there is a comparison group: Researchers will compare Parks and Bacon operation to see if the anal function 1 year after surgery is different.",[171,27,172,68],"Rectal Neoplasms","Anastomotic Leak",[174,175,176],"anal function","Parks technique","Bacon technique","2025-12-11",{"date":179,"type":36},"2025-12-18",{"date":181,"type":36},"2023-08-08",{"date":183,"type":20},"2027-08-08",{"name":185,"class":43},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":44},"100571254","retrograde-and-antegrade-enema-for-prevention-of-lars-after-lar-a-randomized-controlled-trial-100571254","NCT06717854","Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial","Retrograde and Antegrade Enema for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Based on the NCCN guidelines for the pathological diagnosis of rectal cancer, patients are identified as having Primary Rectal Adenocarcinoma.\n* ≥18 years.\n* For the first time, anterior rectal dissection combined with prophylactic ileostomy was performed using laparoscopic, robotic, and open techniques.\n* The patient exhibits normal cognitive and expressive abilities.\n* Informed consent was obtained for voluntary participation in the study.\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) Class III or higher.\n* A combination of other intestinal conditions, including inflammatory bowel disease and Crohn's disease.\n* Mental disorders and prolonged use of psychotropic medications.\n* The presence of contraindications to enema administration.","80 Years",{"count":195,"type":20},72,[23],"The goal of this clinical trial is to learn if enema works to prevent low anterior resection syndrome (LARS) in adults. The main questions it aims to answer are:\n\n1. To describe the level of stoma adaptation before and after the patients received enemas during the stoma period as well as the levels and trends of LARS, bowel function, sleep quality, and quality of life after stoma reduction surgery\n2. To compare the effects and advantages and disadvantages of antegrade and retrograde enema, and to investigate whether these two types of enema can provide safe and effective preventive measures for the prevention of LARS, the improvement of bowel function, and the enhancement of sleep and quality of life in rectal cancer patients after low anterior resection.\n\nResearchers will compare antegrade enema, retrograde enema, and the standard of care to see if these two types of enema work to prevent LARS.\n\nParticipants will:\n\n1. Receive either antegrade or retrograde enema or no enema based on the standard of care at 1 month after anterior rectal resection, until the ileostomy reversal.\n2. Keep a diary of their symptoms.",[27],"2025-03-25",{"date":201,"type":36},"2025-03-30",{"date":199,"type":20},{"date":204,"type":20},"2026-12-30",{"name":206,"class":43},"Sichuan Cancer Hospital and Research Institute",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":218,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":44},"100577284","transanal-irrigation-for-low-anterior-resection-syndrome-100577284","NCT06796296","Transanal Irrigation for Low Anterior Resection Syndrome","The Safety and Efficacy of Transanal Irrigation in Patients from Low Anterior Resection Syndrome After Rectal Cancer Surgery : a Multicenter Prospective Randomized Controlled Trial (TraLARS Study)","TraLARS","Inclusion Criteria:\n\n* Adults aged 19 years and above.\n* Patients who have undergone low or ultra-low anterior resection surgery for rectal cancer (within 15cm from the anal verge).\n* Patients at least 24 months post-surgery without stoma.\n* Patients evaluated with a major LARS score.\n* Patients who comprehend and have the ability to participate in this clinical trial.\n\nExclusion Criteria:\n\n* Patients with recurrent colorectal cancer.\n* Patients with concomitant metastatic colorectal cancer.\n* Patients requiring permanent colostomy.\n* Patients who have undergone postoperative cancer radiation therapy.\n* Patients with underlying conditions not controlled by internal medical treatment.\n* Patients with inflammatory bowel disease (IBD).\n* Patients with symptoms of constipation or diarrhea not controlled by medication.\n* Patients with preoperative symptoms of fecal incontinence.\n* Patients allergic to the investigational drug.\n* Patients deemed unsuitable for clinical trial participation by the principal investigator and study personnel.","19 Years",{"count":217,"type":20},94,[23],"The preservation surgery of the anal sphincter muscle has become the standard procedure in the treatment of rectal cancer and, thanks to advancements in surgical techniques, can now be performed for tumors located closer to the anus. This method allows patients to avoid a permanent artificial anus, maintaining continuity of the intestines and enabling bowel movements through the anus, making it a highly preferred procedure. Furthermore, advancements in various tumor treatments have led to improved long-term survival rates.\n\nPreservation surgery of the anal sphincter muscle is commonly used in the treatment of rectal cancer, resulting in approximately 90% of patients experiencing changes in bowel habits after surgery. These changes include characteristic diarrhea, urgent bowel movements, frequent bowel movements, and fecal incontinence, collectively known as Anterior Resection Syndrome (ARS). Particularly in the case of low rectal cancer, it often manifests as Low Anterior Resection Syndrome (LARS). These symptoms are most severe immediately after surgery, generally persisting in a significant degree for 1-2 years, with some improvement over time. However, for many patients, LARS remains a lifelong challenge, significantly impacting their quality of life. Nighttime symptoms of LARS, in particular, have a profound effect on sleep quality, potentially leading to a decline in overall quality of life.\n\nCurrently, there is no definitive method to completely cure LARS, and the available approaches focus on empirical treatments or short-term symptom control using medications such as loperamide.\n\nLoperamide directly affects the neuromuscular system of the intestine, reducing its motility. This prolongs the time food stays in the intestine, allowing sufficient absorption of moisture and electrolytes, consequently reducing symptoms of diarrhea. Loperamide is available in two forms: loperamide oxide and loperamide hydrochloride. While loperamide oxide products like Arestal® were prescribed by doctors until August 2017, the approval was revoked, leaving loperamide hydrochloride as the only form used domestically. It comes in a single product containing 2 mg of loperamide hydrochloride and a combination product with 0.25 mg of loperamide hydrochloride, a sterilizing agent in the intestine (e.g., acrylonitrile, berberine), and an antispasmodic.\n\nTransanal irrigation (TAI) is a method where patients self-administer water into the rectum through an enema, physically cleansing the anus and rectum. This technique is often used for patients with chronic constipation or fecal incontinence. TAI has proven beneficial, particularly in improving symptoms for patients experiencing bowel dysfunction following sphincter-preserving surgery, especially for those who underwent low anterior resection.\n\nHowever, there is currently no research on the utility and safety of TAI for LARS patients, specifically addressing whether it can improve the nighttime symptoms associated with LARS syndrome and enhance sleep quality. Therefore, this study aims to investigate the impact of TAI on the symptoms of LARS syndrome.",[27,221,222],"Rectal Cancer Surgery","Insomnia",[29,224],"Low anterior resection syndrome","2025-01-21",{"date":227,"type":36},"2025-01-28",{"date":229,"type":20},"2025-02-01",{"date":231,"type":20},"2029-12-31",{"name":233,"class":43},"Seoul National University Hospital",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":44},"100559886","the-effects-of-colorectal-prehabilitation-via-reinfusion-or-retention-enema-of-ileal-contents-filtrate-on-the-defecation-functions-for-the-lar-patients-with-ileostomy-before-stoma-closure-100559886","NCT06569966","The Effects of Colorectal Prehabilitation Via Reinfusion or Retention Enema of Ileal Contents Filtrate on the Defecation Functions for the LAR Patients With Ileostomy Before Stoma Closure","The Effects of Colorectal Prehabilitation Via Reinfusion or Retention Enema of Ileal Contents Filtrate on the Defecation Functions for the LAR Patients With Ileostomy Before Stoma Closure: A Single Center Prospective Randomized Controlled Study","Inclusion Criteria:\n\n* aged 18-85 years old\n* Karnofsky performance status (KPS)≥70%; Or ECOG score 2 points or less\n* rectal cancer confirmed by preoperative pathology\n* in the rectum resection before low, low colorectal anastomosis or after neoadjuvant therapy of patients\n* prophylactic ileostomy.\n\nExclusion Criteria:\n\n* cannot complete treatment\n* the history of the anorectal surgery\n* preoperative bowel dysfunction such as diarrhea, irritable bowel syndrome and functional constipation, etc.)\n* postoperative anastomotic fistula and stricture\n* during pregnancy or breastfeeding women\n* with uncontrolled seizures, central nervous system disease or a history of mental disorders\n* the last five years have other history of malignant disease cured except skin cancer and cervical carcinoma in situ\n* clinically significant (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association class II or worse 9) severe congestive heart failure or major arrhythmia requiring medical intervention, or myocardial infarction within the previous 6 months\n* has a history of cerebral infarction or cerebral hemorrhage within the past 6 months\n* organ transplantation requiring immunosuppressive therapy\n* serious uncontrolled repeated infections, or other serious with disease of control;\n* moderate or severe renal impairment creatinine clearance equal to or less than 50ml\u002Fmin, or upper limit of normal (ULN)\n* emergency surgery due to tumor emergencies (bleeding, perforation, obstruction)\n* in screening the first 4 weeks received study medication or treatment (to participate in other test).","85 Years",{"count":243,"type":20},154,[23],"This study was a single-center RCT study to compare the effect of preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon with that of traditional treatment in patients with bowel function after stoma closure.",[27],"2024-08-22",{"date":249,"type":36},"2024-08-26",{"date":251,"type":36},"2021-07-01",{"date":253,"type":20},"2024-12",{"name":255,"class":43},"The Affiliated Hospital of Qingdao University",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":241,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":273,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":44},"100556381","effect-of-pelvic-rehabilitation-after-low-anterior-resection-for-cancer-rectum---a-randomised-controlled-trial-100556381","NCT06524362","Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial","Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial (PERECARE TRIAL)","PERECARE","Inclusion Criteria:\n\n* Age: Adults aged 18 years or older.\n* Surgical Procedure: Have undergone Low Anterior Resection (LAR) for rectal cancer.\n* Cognitive Ability: Capable of understanding and completing the questionnaires effectively\n\nExclusion Criteria:\n\n* Medical History: History of proctitis, ulcerative colitis, or Crohn's disease.\n* Surgical Extent: Extensive resection (beyond Total Mesorectal Excision - TME) for\n* locally advanced (T4) tumors, patients undergoing APR.\n* Surgical Complications: History of anastomotic leakage.\n* Recent Physiotherapy: History of invasive physiotherapy within the past 6 months.\n* Mental or Physical Inabilities: Inability to undergo Pelvic Floor Rehabilitation due to mental or physical limitations",{"count":265,"type":20},77,[23],"Study Purpose:\n\nThis study aims to understand how pelvic floor rehabilitation (PFR) after low anterior resection (LAR) surgery for rectal cancer affects bowel control and quality of life compared to usual care.\n\nBackground:\n\nRectal cancer and its treatments can significantly impact patients' lives, often causing bowel issues like frequent bowel movements, urgency, and incontinence. These problems, known as low anterior resection syndrome (LARS), affect 70-90% of patients and can last for over two years. (1,2)\n\nCurrent Knowledge:\n\nAdvances in treatments have improved survival rates and recovery. Despite improvements, many patients still experience bowel issues after surgery.\n\nPast studies show PFR can help, but they have limitations like small sample sizes and varied methods. (3-5)\n\nNeed for the Study:\n\nThere is a need for a well-designed study to confirm the benefits of PFR and to identify which patients benefit the most.\n\nStudy Design:\n\nThis study is a randomized controlled trial that will:\n\n* Compare PFR to usual care in patients after LAR surgery.\n* Focus on bowel control and quality of life.\n* Provide detailed insights to improve aftercare for rectal cancer patients.",[59,269,171,270,27,271,272],"Rectum Neoplasm","Rectal Adenocarcinoma","Fecal Incontinence","Bowel Dysfunction",[274,275,276,221,277,278,279,280,281,282,283],"Pelvic Floor Rehabilitation","Low Anterior Resection","Ultra Low Anterior Resection","Post operative care","Bowel function","Quality of life","Randomized controlled trial","Fecal Urgency","Pelvic Floor Muscle Training","Oncological outcomes","2024-07-23",{"date":286,"type":36},"2024-07-29",{"date":288,"type":20},"2024-08",{"date":290,"type":20},"2026-03",{"name":292,"class":43},"GEM Hospital & Research Center",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":193,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":4},"100552618","fecal-microbiota-transplantation-in-the-treatment-of-major-lars-100552618","NCT06475430","Fecal Microbiota Transplantation in the Treatment of Major LARS","Evaluation of the Effectiveness of Fecal Microbiota Transplantation in the Treatment of Patients With Severe Low Anterior Resection Syndrome (LARS)","FMT-LARS","Inclusion Criteria:\n\n\\- Age ≥ 18 years old, regardless of gender; Patients with rectal cancer who have undergone total mesorectal excision (TME) and sphincter-preserving surgery, and the postoperative period is more than 3 months; Patients with a LARS score of 21 to 42; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Expected survival period ≥ 1 year; Voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n\\- Patients with pre-operative symptoms of fecal and urinary incontinence; Patients who have undergone pelvic surgery or LAR due to non-cancerous reasons; Patients who have undergone pelvic radiotherapy; Patients with prophylactic ostomy; Patients who have used any antibiotic medication, probiotic products, or prebiotic products in the past 4 weeks; Patients who have regularly used laxatives in the past two weeks; Pregnant or lactating women; Human immunodeficiency virus (HIV) positive; Known history of active pulmonary tuberculosis (TB). Subjects suspected of having active TB require chest X-ray, sputum examination, and exclusion based on clinical symptoms and signs; Untreated patients with chronic hepatitis B or HBV carriers with HBV DNA exceeding 500 IU\u002FmL, or patients with active hepatitis C should be excluded. Non-active HBsAg carriers, treated and stable hepatitis B patients (HBV DNA \\\u003C 500 IU\u002FmL), and cured hepatitis C patients can be enrolled. For subjects with positive HCV antibodies, only those with negative HCV RNA test results are eligible to participate in the study; Known history of psychiatric drug abuse, alcoholism, and drug abuse; Patients with cognitive impairment; Any situation where the investigator believes the participant should be excluded from the study.",{"count":302,"type":20},40,[23],"Randomized trial to assess FMT efficacy in improving bowel function for major LARS patients. 40 subjects, blinded, randomized to FMT or probiotics. Pre-post 16S sequencing, 4-week follow-up for bowel symptoms, 8-week microbiota analysis.",[27,306],"Fecal Microbiota Transplantation",[148,308,309,310],"bowel function","fecal microbiota transplantation","intestinal microbiota","2024-06-20",{"date":313,"type":36},"2024-06-26",{"date":315,"type":20},"2025-01-01",{"date":108,"type":20},{"name":318,"class":43},"Peking University People's Hospital",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":213,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":193,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":44},"100533164","the-safety-and-efficacy-of-transanal-irrigation-in-patients-with-sleep-disturbance-from-low-anterior-resection-syndrome-after-rectal-cancer-surgery-tralars-100533164","NCT06222255","The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery (TraLARS)","The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery: A Multicenter Prospective Randomized Controlled Trial (TraLARS)","Inclusion Criteria:\n\n1. Adults aged 19 years and above.\n2. Patients who have undergone low or ultra-low anterior resection surgery for rectal cancer (within 15cm from the anal verge).\n3. Patients at least 24 months post-surgery (excluding those with incontinence, patients who have undergone postoperative cancer treatment should have completed treatment, and patients who have undergone bowel restoration surgery should be at least 6 months post-surgery, or for patients who received long-course preoperative radiotherapy, at least 18 months post-surgery).\n4. Patients evaluated with a major LARS score who also have an ISI score of 3 or 4.\n5. Patients who comprehend and have the ability to participate in this clinical trial.\n\nExclusion Criteria:\n\n1. Patients currently taking medication for LARS within the last month.\n2. Patients with a history of prior surgery for colorectal cancer.\n3. Patients with recurrent colorectal cancer.\n4. Patients with concomitant metastatic colorectal cancer.\n5. Patients requiring permanent colostomy.\n6. Patients who have undergone postoperative cancer radiation therapy.\n7. Patients with underlying conditions not controlled by internal medical treatment.\n8. Patients with inflammatory bowel disease (IBD).\n9. Patients with symptoms of constipation or diarrhea not controlled by medication.\n10. Patients with preoperative symptoms of fecal incontinence.\n11. Patients allergic to the investigational drug.\n12. Patients deemed unsuitable for clinical trial participation by the principal investigator and study personnel.\n13. Patients with ISI scores of 1 or 2.",{"count":327,"type":20},52,[23],"The preservation surgery of the anal sphincter muscle has become the standard procedure in the treatment of rectal cancer and, thanks to advancements in surgical techniques, can now be performed for tumors located closer to the anus. This method allows patients to avoid a permanent artificial anus, maintaining continuity of the intestines and enabling bowel movements through the anus, making it a highly preferred procedure. Furthermore, advancements in various tumor treatments have led to improved long-term survival rates.\n\nPreservation surgery of the anal sphincter muscle is commonly used in the treatment of rectal cancer, resulting in approximately 90% of patients experiencing changes in bowel habits after surgery. These changes include characteristic diarrhea, urgent bowel movements, frequent bowel movements, and fecal incontinence, collectively known as Anterior Resection Syndrome (ARS). Particularly in the case of low rectal cancer, it often manifests as Low Anterior Resection Syndrome (LARS). These symptoms are most severe immediately after surgery, generally persisting in a significant degree for 1-2 years, with some improvement over time. However, for many patients, LARS remains a lifelong challenge, significantly impacting their quality of life. Nighttime symptoms of LARS, in particular, have a profound effect on sleep quality, potentially leading to a decline in overall quality of life.\n\nCurrently, there is no definitive method to completely cure LARS, and the available approaches focus on empirical treatments or short-term symptom control using medications such as loperamide.\n\nLoperamide directly affects the neuromuscular system of the intestine, reducing its motility. This prolongs the time food stays in the intestine, allowing sufficient absorption of moisture and electrolytes, consequently reducing symptoms of diarrhea. Loperamide is available in two forms: loperamide oxide and loperamide hydrochloride. While loperamide oxide products like Arestal® were prescribed by doctors until August 2017, the approval was revoked, leaving loperamide hydrochloride as the only form used domestically. It comes in a single product containing 2 mg of loperamide hydrochloride and a combination product with 0.25 mg of loperamide hydrochloride, a sterilizing agent in the intestine (e.g., acrylonitrile, berberine), and an antispasmodic.\n\nTransanal irrigation (TAI) is a method where patients self-administer water into the rectum through an enema, physically cleansing the anus and rectum. This technique is often used for patients with chronic constipation or fecal incontinence. TAI has proven beneficial, particularly in improving symptoms for patients experiencing bowel dysfunction following sphincter-preserving surgery, especially for those who underwent low anterior resection.\n\nHowever, there is currently no research on the utility and safety of TAI for LARS patients, specifically addressing whether it can improve the nighttime symptoms associated with LARS syndrome and enhance sleep quality. Therefore, this study aims to investigate the impact of TAI on the quality of sleep in patients with nighttime symptoms of LARS syndrome.",[27,59,222,331],"Sleep Disorder","2024-01-22",{"date":334,"type":36},"2024-01-24",{"date":336,"type":36},"2023-12-06",{"date":131,"type":20},{"name":233,"class":43},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":31,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":44},"100467546","impact-of-early-postoperative-treatment-with-posterior-tibial-nerve-stimulation-on-the-incidence-and-duration-of-low-anterior-rectal-resection-syndrome-100467546","NCT05368168","Impact of Early Postoperative Treatment With Posterior Tibial Nerve Stimulation on the Incidence and Duration of Low Anterior Rectal Resection Syndrome","Inclusion Criteria:\n\n* Patients undergoing elective surgery (scheduled, non-urgent) who underwent anterior rectal resection or transit reconstruction with low anastomosis (below 10 cm from the anal margin) at the Hospital Álvaro Cunqueiro in Vigo after the start date of the study.\n* Anastomotic tightness (absence of dehiscence).\n* Patients older than 18 years old.\n* Acceptance to participate in the study.\n\nExclusion Criteria:\n\n* Inability to understand the study instructions and recommendations.\n* Dementia or any type of mental disability.\n* Palliative surgery.\n* Patients with pacemakers.\n* Anti-coagulated patients.\n* Patients with trophic lesions on the skin of the ankles.",{"count":346,"type":20},114,[23],"The treatment of rectal cancer is currently based on surgical resection of the rectum with total excision of the mesorectum, associated with neoadjuvant radiochemotherapy.\n\nSurgical resections with sphincter preservation are frequently (60% of cases) associated with problems related to intestinal and defecatory function, which together are called Anterior Resection Syndrome (ARS) with varying degrees of severity.\n\nAmong the different treatments the investigators find posterior tibial nerve stimulation, a simple and non-invasive technique, which is currently used.\n\nThe study aims to analyze whether postoperative posterior tibial nerve stimulation in patients undergoing low anterior resection of the rectum has an impact on the incidence and duration of low anterior resection syndrome (LARS) and therefore on the quality of life of patients undergoing this type of intervention.\n\nTherefore, treatment with PNTS is currently established for the management of LARS symptoms. Given that a large percentage of patients operated on for rectal neoplasms will develop this syndrome, the investigators intend to apply this treatment before the onset of symptoms in patients at risk for LARS. It is also an intervention with a low rate of side effects, the benefit that the investigators can obtain from its preventive application is clearly superior to the risk of undergoing such treatment.\n\nThe investigators´ hypothesis is: Posterior tibial stimulation for 6 weeks post-operative of low anterior resection with anastomosis has a favorable impact by reducing the incidence and duration of ARS and improving the quality of life of patients undergoing anterior rectal resections for cancer.",[350,27,275],"Rectal Disorders",[352,353,354],"Posterior tibial nerve stimulation (PTNS)","Urgent PC","Transcutaneous neurostimulator","2023-07-05",{"date":357,"type":36},"2023-07-06",{"date":359,"type":36},"2022-06-03",{"date":361,"type":20},"2027-01",{"name":363,"class":43},"Innovacion en Cirugía Vigo",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":372,"minAge":17,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":44},"100472411","assessment-of-quality-of-life-after-low-anterior-resection-during-cytoreductive-surgery-for-advanced-ovarian-cancer-100472411","NCT05431530","Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer","Assessment of Quality of Life After Low Anterior Resection or Visceral Peritoneal Stripping During cytOreDuctive surgerY for Advanced Ovarian Cancer Requiring Tumor Resection on the Rectosigmoid Colon: a Prospective Cohort Study","LAPSODY","Inclusion Criteria:\n\n* Those with newly diagnosed ovarian cancer, fallopian tube cancer and primary peritoneal carcinomatosis who plan to undergo cytoreductive surgery and secondary cytoreductive surgery after neoadjuvant chemotherapy.\n* Patients with PCDS or rectal and sigmoid coloni tumor invasion suspected on the preoperative image and need resection of the tumor and clinical FIGO stage IIIB or higher\n* ECOG performance status : 0-2\n* Age over 18\n\nExclusion Criteria:\n\n* Patient who underwent low anterior resection in the past\n* Past history of gastrointestinal malignant tumor except to ovarian cancer\n* Patient who have colostomy\n* Patient who underwent radiation therapy to abdominal or pelvic cavity\n* ECOG performance status over 3\n* Patient taking opioid analgesics\n* Patient who have intellectual disability or dementia","FEMALE",{"count":374,"type":20},108,"This study aims to evaluate the incidence of low anterior resection syndrome and quality of life after cytoreductive surgery for advanced ovarian cancer patients.",[377,27,68],"Ovarian Cancer","2023-06-25",{"date":380,"type":36},"2023-06-27",{"date":382,"type":36},"2022-06-22",{"date":384,"type":20},"2027-05-31",{"name":233,"class":43},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":393,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":21,"phases":395,"briefSummary":396,"conditions":397,"keywords":398,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":44},"100369214","phase-3-comparison-of-transanal-irrigation-and-glycerol-suppositories-in-treatment-of-low-anterior-resection-syndrome-100369214","NCT04087421","Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome","Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome: A Multicentre Randomised Controlled Trial","Inclusion Criteria:\n\n* Patients electively treated for rectal cancer with a low anterior resection.\n* Unsuccessful PCT after at least 4 weeks of treatment for LARS (LARS score \\>29 at evaluation).\n* At least 3 months after surgery (including reversal of a temporary loop-ileostomy).\n* Age \\>= 18 years\n* Ability to understand written and spoken language actual for the including site (due to questionnaire validity).\n\nExclusion Criteria:\n\n* Former use of TAI\n* Prior systematic use of rectal emptying aids\n* Anastomotic stenosis\n* History of anastomotic leakage\n* Current metastatic disease or local recurrence\n* Ongoing oncological treatment\n* Postoperative radiotherapy for rectal cancer\n* Previous or current cancer in other pelvic organs than the rectum\n* Underlying diarrhoeal disease\n* Inflammatory bowel disease\n* Dementia\n* Spinal cord injury, multiple sclerosis, Parkinson's disease or other significant neurologic disease assessed to be a contributory cause to LARS symptoms.\n* Inability of patient to use TAI\n* Inability and unwillingness to give informed consent\n* Pregnancy or intention to become pregnant during the trial period",true,{"count":346,"type":20},[56],"The study is a multicentre randomized controlled trial with the objective to compare the effect of transanal irrigation with glycerol suppositories in patients suffering from major Low Anterior Resection Syndrome (LARS).",[27,59],[27,29,399],"Glycerol suppositories","2023-05-01",{"date":402,"type":36},"2023-05-03",{"date":404,"type":36},"2019-09-17",{"date":406,"type":20},"2026-12",{"name":408,"class":43},"University of Aarhus"]